Comparative Pharmacology
Head-to-head clinical analysis: NITRO IV versus NITROMIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITRO IV versus NITROMIST.
NITRO IV vs NITROMIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitroglycerin is a vasodilator that primarily acts by relaxing vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase to increase cGMP, leading to venodilation and, at higher doses, arterial dilation. This reduces preload and afterload, decreasing myocardial oxygen demand.
Nitroglycerin is a prodrug that releases nitric oxide (NO) which activates guanylyl cyclase, increasing cGMP in smooth muscle cells, leading to vasodilation primarily of venous capacitance vessels and coronary arteries.
Initial infusion rate 5 mcg/min via continuous IV infusion, titrate by 5 mcg/min every 3-5 minutes until response; usual maintenance dose 10-20 mcg/min; maximum 200 mcg/min.
1-2 sprays (0.4-0.8 mg) sublingually or intraorally at onset of angina, may repeat every 5 minutes up to 3 doses. Prophylaxis: 1 spray (0.4 mg) 5-10 minutes before activity.
None Documented
None Documented
1-4 minutes (rapidly cleared from blood); terminal half-life ~2-3 minutes due to rapid biotransformation in RBCs and vascular tissue.
2–3 minutes for nitroglycerin; rapid metabolism results in short terminal half-life. Clinically, effects dissipate within 30 minutes of discontinuation.
Renal (minimal, <1% unchanged) and hepatic metabolism; metabolites excreted renally.
Renal excretion of inactive metabolites accounts for >80% of elimination; biliary/fecal excretion is minimal (<15%).
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator